

# Errata and Technical Corrections – CPT<sup>®</sup> 2023 Date: March 1, 2023

The information that follows is sourced to either a publication errata or a technical correction by the CPT Editorial Panel. An errata (denoted as **E**) for the current edition of the CPT code set will publish information that was approved by the CPT Editorial Panel and inadvertently excluded from the current code set. Technical corrections (denoted as **T**) are clarifications of original Panel intent for the current code structure. All items below are errata if they are not designated as a technical correction in the right-hand column. The order of the entries on this document is by code order. Additionally, each entry shows the date of publication to this document. The links immediately following are provided as a guide to the most recently added items. **The effective date for each item is January 1, 2023**. Updates to this document are made as issues surface requiring clarification.

#### Most recent entries added to Errata and Technical Corrections - CPT® 2023

- Revise definition of "Independent interpretation" to add: "A test that is ordered and independently interpreted may count as both a test ordered and interpreted"; and definition of "Appropriate source" to add: "For the purpose of documents reviewed, documents from an appropriate source may be counted" in the Amount and/or Complexity of Data to Be Reviewed and Analyzed subsection.
- Revise guideline by removing "A patient is considered an outpatient until inpatient admission to a health care facility occurs" in the Evaluation and Management Office or Other Outpatient Services subsection.
- Remove "180 or More Days" in the Dosing Interval section for code 91300 in Appendix Q.

#### Evaluation and Management (E/M) Services Guidelines Levels of E/M Services Amount and/or Complexity of Data to Be Reviewed and Analyzed

Posted 3/01/23

Independent interpretation: The interpretation of a test for which there is a CPT code, and an interpretation or report is customary. This does not apply when the physician or other qualified health care professional who reports the E/M service is reporting or has previously reported the test. A form of interpretation should be documented but need not conform to the usual standards of a complete report for the test. A test that is ordered and independently interpreted may count both as a test ordered and interpreted.

**Appropriate source:** For the purpose of the **discussion of management** data element (see Table 1, Levels of Medical Decision Making), an appropriate source includes professionals who are not health care professionals but may be involved in the management of the patient (eg, lawyer, parole officer, case manager, teacher). It does not include discussion with family or informal caregivers. For the purpose of **documents reviewed**, documents from an appropriate source may be counted.

Revise definition of "Independent interpretation" to add: "A test that is ordered and independently interpreted may count as both a test ordered and interpreted"; and definition of "Appropriate source" to add: "For the purpose of documents reviewed, documents from an appropriate source may be counted" in the Amount and/or Complexity of Data to Be Reviewed and Analyzed subsection.

CPT is a registered trademark of the American Medical Association Copyright 2023, American Medical Association All rights reserved. Updated: March 1, 2023

Evaluation and Management Office or Other Outpatient Services		Posted 3/01/23		
The following codes are used to report evaluation and management services provided in the office or in an outpatient or other ambulatory facility. A patient is considered an outpatient until inpatient admission to a health care facility occurs.				
Revise guideline by removing "A patient is considere health care facility occurs" in the Evaluation and Masubsection.				
Evaluation and Management Nursing Facility Services		Posted 12/22/22 E		
The following codes are used to report evaluation and magnitudes and skilled nursing facilities. These codes shoul management services provided to a patient in a psychial intermediate care facility for individuals with intellectual contents. Revise guideline by replacing the term "immediate" of the term "immediate" of the term "immediate".	d also be used to report evaluation and irric residential treatment center and immediate lisabilities.			
and Management Nursing Facility Services subsection  Evaluation and Management  Prolonged Services  Prolonged Service With or Without Direct Patient Co  Management Service		Posted 2/01/23 E		
Total Duration of Office or Other Outpatient Consultation Services (use with 99245)	Code(s)			
less than 70 minutes	Not reported separately			
70-84 minutes	99245 X 1 and 99417 X 1			
8085-99 minutes	99245 X 1 and 99417 X 2			
100 minutes or more	99245 X 1 and 99417 X 3 or more for each additional 15 minutes			
Revise the time range in the Total Duration of Office table for codes 99245 X 1 and 99417 X 2 by replacing Prolonged Service With or Without Direct Patient Co	80 with 85 in the Evaluation and Management			
Surgery Cardiovascular System Heart and Pericardium Endovascular Repair of Congenital Heart and Vascul	lar Defects	Posted 2/01/23 E		

CPT is a registered trademark of the American Medical Association Copyright 2023, American Medical Association All rights reserved. Updated: March 1, 2023

Diagnostic cardiac catheterization and diagnostic angiography codes (93451, 93452, 93453, 93454, 93455, 93456, 93457, 93458, 93459, 93460, 93461, 93563, 93566, 93567, 93568, 93593, 93594, 93596. 93597, 93598) should **not** be used with 33900, 33901, 33902, 33903, 33904 to report: 1. Contrast injections, angiography, roadmapping, and/or fluoroscopic guidance for the <del>TPVI</del>percutaneous pulmonary artery revascularization by stent placement. 2. Pulmonary conduit angiography for guidance of <del>TPVI</del>percutaneous pulmonary artery revascularization by stent placement, or 3. Right heart catheterization for hemodynamic measurements before, during, and after TPVIpercutaneous pulmonary artery revascularization by stent placement for guidance of TPVIpercutaneous pulmonary artery revascularization by stent placement. Revise guidelines by replacing "TPVI" with "percutaneous pulmonary artery revascularization by stent placement" in the Surgery Endovascular Repair of Congenital Heart and Vascular Defects subsection. Surgery **Posted Digestive System** 12/22/22 Intestines (Except Rectum) **Other Procedures** 44705 Preparation of fecal microbiota for instillation, including assessment of donor specimen (Do not report 44705 in conjunction with 74283, 0780T) (For fecal instillation by oro-nasogastric tube or enema, use 44799) (For instillation of fecal microbiota suspension via rectal enema, use 0780T) Revise parenthetical note following code 44705 by removing the term "or enema" from the Surgery Other Procedures subsection. Surgery **Posted Urinary System** 11/01/22 Bladder Т **Transurethral Surgery Urethra and Bladder** 52281 Cystourethroscopy, with calibration and/or dilation of urethral stricture or stenosis, with or without meatotomy, with or without injection procedure for cystography, male or female (To report cystourethroscopy with urethral therapeutic drug delivery, use 0499T) Reinstate code 0499T and the related parenthetical note following code 52281 in the Surgery Urethra and Bladder subsection. Medicine **Posted** Cardiovascular 11/01/22 **Noninvasive Physiologic Studies and Procedures** E

Bioimpedance-derived physiologic cardiovascular analysis

93701

(For bioelectrical impedance analysis whole body composition, use 0358T. For left ventricular filling pressure indirect measurement by computerized calibration of the arterial waveform response to Valsalva, use 93799)

93745 93702 Bioimpedance spectroscopy (BIS), extracellular fluid analysis for lymphedema assessment(s)

(For bioelectrical impedance analysis whole body composition, use 0358T)

(For bioimpedance-derived physiological cardiovascular analysis, use 93701)

Correct duplication error following code 93701 in the Medicine Noninvasive Physiologic Studies and Procedures subsection by replacing code 93745 with code 93702 in the printed publication of CPT® 2023 codebook.

### Pathology and Laboratory Genomic Sequencing Procedures and Other Molecular Multianalyte Assays

Posted 12/22/22 E

Genomic sequencing procedures (GSPs) and other molecular multianalyte assays GSPs are DNA or RNA sequence analysis methods that simultaneously assay multiple genes or genetic regions relevant to a clinical situation. They may target specific combinations of genes or genetic material, or assay the exome or genome. The technology typically used for genomic sequencing is referred to as next generation sequencing (NGS) or massively parallel sequencing (MPS) although other technologies may be employed. GSPs are performed on nucleic acids from germline or neoplastic samples. Examples of applications include an euploidy analysis of cell-free circulating fetal DNA, gene panels for somatic alterations in neoplasms, and sequence analysis of the exome or genome to determine the cause of developmental delay. The exome and genome procedures are designed to evaluate the genetic material in totality or near totality. Although commonly used to identify sequence (base) changes, they can also be used to identify copy number, structural changes, and abnormal zygosity patterns which may be performed in combination or may require separately performed methods and analyses. Another unique feature of GSPs is the ability to "re-query" or re-evaluate the sequence data (eg, complex phenotype such as developmental delay is reassessed when new genetic knowledge is attained, or for a separate unrelated clinical indication). The analyses listed below represent groups of genes that are often performed by GSPs; however, the analyses may also be performed by other molecular techniques (eq. polymerase chain reaction [PCR] methods and microarrays). These codes should be used when the components of the descriptor(s) are fulfilled regardless of the technique used to provide the analysis, unless specifically noted in the code descriptor. When a GSP assay includes gene(s) that is listed in more than one code descriptor, the code for the most specific test for the primary disorder sought should be reported, rather than reporting multiple codes for the same gene(s). When all of the components of the descriptor are not performed, use individual Tier 1 codes, Tier 2 codes, or 81479 (Unlisted molecular pathology procedure).

Testing for somatic alterations in neoplasms may be reported differently based on whether combined methods and analyses are used for both DNA and RNA analytes, or if separate methods and analyses are used for each analyte (DNA analysis only, RNA analysis only). For targeted genomic sequence DNA analysis or DNA and RNA analysis using a single combined method, report 81445, 81450, or 81455. For targeted genomic sequence RNA analysis when performed using a separate method, report 81449, 81451, 81456. For targeted genomic sequence DNA analysis and RNA analysis performed separately rather than via a combined method, report 81445, 81450, or 81455 for the DNA analysis and report 81449, 81451, or 81456 for the RNA analysis.

**Low-pass sequencing:** a method of genome sequencing intended for cytogenomic analysis of chromosomal abnormalities, such as that performed for trait mapping or copy number variation, typically performed to an average depth of sequencing ranging from 0.1 to 5X.

The assays in this section represent discrete genetic values, properties, or characteristics in which the measurement or analysis of each analyte is potentially of independent medical significance or useful in medical management. In contrast to multianalyte assays with algorithmic analyses (MAAAs), the assays in this section do not represent algorithmically combined results to obtain a risk score or other value, which in itself represents a new and distinct medical property that is of independent medical significance relative to the individual, component test results. (For cytogenomic [genome-wide] analysis for constitutional chromosomal abnormalities, see 81228, 81229, 81349, 81405, 81406) Revise parenthetical note by adding code 81349 in the Pathology and Laboratory Genomic Sequencing Procedures and Other Molecular Multianalyte Assays subsection. **Category III Codes Posted** 11/01/22 0499T Cystourethroscopy, with mechanical dilation and urethral therapeutic drug delivery for Т urethral stricture or stenosis, including fluoroscopy, when performed Sunset January 20238 (Do not report 0499T in conjunction with 52281, 52283) ► (0499T has been deleted) < ► (For cystourethroscopy with urethral therapeutic drug delivery, use 53899) < 0619T Cystourethroscopy with transurethral anterior prostate commissurotomy and drug delivery, including transrectal ultrasound and fluoroscopy, when performed Los not report 0619T in conjunction with 52000, 52441, 52442, 52450, 52500, 52601, 52630, 52640, 52647, 52648, 52649, 53850, 53852, 53854, 76872, 0499T) Reinstate code 0499T in the listing of Category III codes and in the parenthetical note following code 0619T. Extend sunset date from January 2023 to January 2028 for code 0499T Appendix P **Posted CPT Codes That May Be Used For Synchronous Telemedicine Services** 11/01/22 Т This listing is a summary of CPT codes that may be used for reporting synchronous (real-time) telemedicine services when appended by modifier 95. Procedures on this list involve electronic communication using interactive telecommunications equipment that includes, at a minimum, audio and video. The codes listed below are identified in CPT 2023 with the ★ symbol.

90785	90970	96164	99212	
90791	92227	<u>96165</u>	99213	
90792	92228	96167	99214	
90832	92507	96168	99215	
90833	92508	96170	99231	
90834	92521	96171	99232	
90836	92522	97110	99233	
90837	92523	97112	99242	
90838	92524	97116	99243	
90839	92526	97161	99244	
90840	92601	97162	99245	
90845	92602	97165	99252	
90846	92603	97166	99253	
90847	92604	97530	99254	
90863	93228	97535	99255	
90951	93229	97750	99307	
90952	93268	97755	99308	
90954	93270	97760	99309	
90955	93271	97761	99310	
90957	93272	97802	99406	
90958	96040	97803	99407	
90960	96105	97804	99408	
90961	96116	98960	99409	
90963	<u>96121</u>	98961	99417	
90964	96125	98962	99418	
90965	<u>96156</u>	99202	99495	
90966	<u>96158</u>	99203	99496	
90967	<u>96159</u>	99204	99497	
90968	96160	99205	99498	
90969	96161	99211		

Add codes 96121, 96156, 96158, 96159, 96164, 96165, 96167, 96168, 96170, and 96171 to the listing of CPT Codes That May Be Used For Synchronous Telemedicine Services section of Appendix P.

## Appendix Q Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) Vaccines

Vaccine Code	Vaccine Administration Code(s)	Patient Age	Vaccine Manufacturer	Vaccine Name(s)	NDC 10/NDC 11 Labeler Product ID (Vial)	Dosing Interval
#91300 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3 mL dosage, diluent reconstituted, for intramuscular use	0001A (1st Dose) 0002A (2nd Dose) 0003A (3rd Dose) 0004A (Booster)	12 years and older	Pfizer, Inc	Pfizer-BioNTech COVID-19 Vaccine/Comirnaty	59267-1000- 1 59267-1000- 01	1st Dose to 2nd Dose: 21 Days  2nd Dose to 3rd Dose: 180 or More Days (CDC recommended population[s] [eg, immunocompromised]): 28 or More Days  Booster: Refer to FDA/CDC Guidance

Posted 11/01/22 E

Posted 3/01/23

CPT is a registered trademark of the American Medical Association Copyright 2023, American Medical Association All rights reserved. Updated: March 1, 2023

#•91311 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 25 mcg/0.25 mL dosage, for intramuscular use	•0111A (1st Dose) •0112A (2nd Dose)	▶6 months through 5 years	►Moderna, Inc ◀	►Moderna COVID-19 Vaccine ◀	▶80777- 279-05 80777-0279- 057 ◀	▶1st Dose to 2nd Dose: 1 Month ◀	
Appendix Q. (11/	01/22)				·	for code 91311 in pendix Q. (3/01/23)	
►Appendix T◀ ►CPT Codes That Services◀	at May Be Use	ed For Synd	chronous Re	eal-Time Interact	tive Audio-C	nly Telemedicine	Posted 11/01/22 T
appended with mo telecommunication	▶This listing is a summary of CPT codes that may be used for reporting audio-only services when appended with modifier 93. Procedures on this list involve electronic communication using interactive telecommunications equipment that includes, at a minimum, audio. The codes listed below are identified in CPT 2023 with the ¶ symbol.◀						
90785 90791 90792 90832 90833 90834 90836 90837 90838 90839 90840 90845 90846 90847 92507	1 00450 0045	92508 92521 92522 92523 92524 96040 96110 96116 96156 96158 96159 96160 96161 96164	0404 00405	96 96 96 96 97 97 97 99 99 99	165 167 168 170 171 802 803 804 406 407 408 409 497 498		
Add codes 96121, 96156, 96158, 96159, 96164, 96165, 96167, 96168, 96170, and 96171 to the listing of CPT Codes That May Be Used For Synchronous Real-Time Interactive Audio-Only Telemedicine Services section of Appendix T.							
Index Canal, Ear See Auditory Can Canalith Reposit Canaleplasty	ioning						Posted 11/01/22 E
Revise index by removing the letter "o" from the term "Canaloplasty" to reflect the term "Canalplasty".							

Short Descriptor Data File 81455 TGSAP SO/HL 51/<> DNA/DNA&RNA  Revise the short descriptor data file by removing the "<" symbol and adding a ">" symbol for code 81455.				
Short Descriptor Data File  81456 TGSAP SO/HL 51/<> RNA ALYS  Revise the short descriptor data file by removing the "<" symbol and adding a ">" symbol for code 81456.	Posted 11/01/22 E			
Medium Descriptor Data File 81455 TGSAP SO/HEMATOLYMPHOID NEO/DO 51/<>DNA/DNA&RNA Revise the medium descriptor data file by removing the "<" symbol and adding a ">" symbol for code 81455.	Posted 11/01/22 E			
Medium Descriptor Data File 81456 TGSAP SO/HEMATOLYMPHOID NEO/DO 51/≤≥RNA ANALYSIS Revise the medium descriptor data file by removing the "<" symbol and adding a ">" symbol for code 81456.	Posted 11/01/22 E			